Drugs / Super Hi-TCR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06902389 | Jul 2025 → Jan 2028 expected | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Super Hi-TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06902389 ↗ |
| Modality | Cell therapy | “Hi-TCR-T cell therapy” NCT06902389 ↗ |
| Route | Intravenous | “administered by peripheral intravenous infusion” NCT06902389 ↗ |